Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANEB NASDAQ:IFRX NASDAQ:MIRA NASDAQ:WHWK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$2.72+10.6%$2.43$0.80▼$3.42$101.07M-0.8944,059 shs63,569 shsIFRXInflaRx$1.25-2.3%$1.25$0.71▼$2.82$85.93M1.4478,612 shs580,865 shsMIRAMIRA Pharmaceuticals$1.32+0.8%$1.38$0.73▼$2.56$24.98M1.69284,093 shs39.70 million shsWHWKWhitehawk Therapeutics$2.10+6.6%$1.86$1.39▼$3.81$92.84M0.58128,807 shs126,353 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals+10.57%+18.26%+10.57%+65.85%+43.16%IFRXInflaRx-2.34%-14.97%+1.63%+44.03%-15.54%MIRAMIRA Pharmaceuticals+0.76%0.00%-4.35%-34.65%+25.71%WHWKWhitehawk Therapeutics+6.60%-1.41%+12.90%+13.51%+209,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$2.72+10.6%$2.43$0.80▼$3.42$101.07M-0.8944,059 shs63,569 shsIFRXInflaRx$1.25-2.3%$1.25$0.71▼$2.82$85.93M1.4478,612 shs580,865 shsMIRAMIRA Pharmaceuticals$1.32+0.8%$1.38$0.73▼$2.56$24.98M1.69284,093 shs39.70 million shsWHWKWhitehawk Therapeutics$2.10+6.6%$1.86$1.39▼$3.81$92.84M0.58128,807 shs126,353 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals+10.57%+18.26%+10.57%+65.85%+43.16%IFRXInflaRx-2.34%-14.97%+1.63%+44.03%-15.54%MIRAMIRA Pharmaceuticals+0.76%0.00%-4.35%-34.65%+25.71%WHWKWhitehawk Therapeutics+6.60%-1.41%+12.90%+13.51%+209,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANEBAnebulo Pharmaceuticals 2.00Hold$5.50102.21% UpsideIFRXInflaRx 2.67Moderate Buy$6.20396.00% UpsideMIRAMIRA Pharmaceuticals 1.00SellN/AN/AWHWKWhitehawk Therapeutics 1.50ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest MIRA, ANEB, WHWK, and IFRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025IFRXInflaRxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025ANEBAnebulo PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025MIRAMIRA PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025WHWKWhitehawk TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/7/2025WHWKWhitehawk TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold9/27/2025ANEBAnebulo PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025IFRXInflaRxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025MIRAMIRA PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025WHWKWhitehawk TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/2/2025IFRXInflaRxHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$6.008/11/2025WHWKWhitehawk TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANEBAnebulo PharmaceuticalsN/AN/AN/AN/A$0.28 per shareN/AIFRXInflaRx$180K466.18N/AN/A$1.13 per share1.11MIRAMIRA PharmaceuticalsN/AN/AN/AN/A$0.13 per shareN/AWHWKWhitehawk Therapeutics$25.98M3.81N/AN/A$2.12 per share0.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANEBAnebulo Pharmaceuticals-$8.48M-$0.260.00∞N/AN/A-80.85%-76.33%N/AIFRXInflaRx-$49.85M-$0.800.00N/AN/AN/A-71.76%-57.68%11/14/2025 (Estimated)MIRAMIRA Pharmaceuticals-$7.85M-$0.490.00N/AN/AN/A-406.70%-328.44%11/11/2025 (Estimated)WHWKWhitehawk Therapeutics-$63.69M-$0.060.00∞N/A99.42%-75.99%-68.57%N/ALatest MIRA, ANEB, WHWK, and IFRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025N/AMIRAMIRA Pharmaceuticals-$0.11N/AN/AN/AN/AN/A9/29/2025Q4 2025ANEBAnebulo Pharmaceuticals-$0.05-$0.05N/A-$0.05N/AN/A8/14/2025Q2 2025MIRAMIRA Pharmaceuticals-$0.11-$0.09+$0.02-$0.09N/AN/A8/7/2025Q2 2025IFRXInflaRx-$0.24-$0.24N/A-$0.24$0.02 million$0.05 million8/7/2025Q2 2025WHWKWhitehawk Therapeutics$0.49-$0.76-$1.25-$0.76$100.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANEBAnebulo PharmaceuticalsN/AN/AN/AN/AN/AIFRXInflaRxN/AN/AN/AN/AN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/AN/AWHWKWhitehawk TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANEBAnebulo PharmaceuticalsN/A24.5124.51IFRXInflaRxN/A4.103.78MIRAMIRA PharmaceuticalsN/A2.802.80WHWKWhitehawk TherapeuticsN/A20.4120.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANEBAnebulo Pharmaceuticals28.40%IFRXInflaRx42.39%MIRAMIRA Pharmaceuticals35.16%WHWKWhitehawk Therapeutics52.08%Insider OwnershipCompanyInsider OwnershipANEBAnebulo Pharmaceuticals80.60%IFRXInflaRx16.30%MIRAMIRA Pharmaceuticals6.65%WHWKWhitehawk Therapeutics49.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANEBAnebulo Pharmaceuticals441.08 million7.97 millionNot OptionableIFRXInflaRx6067.13 million56.19 millionOptionableMIRAMIRA Pharmaceuticals219.07 million17.80 millionNot OptionableWHWKWhitehawk Therapeutics2147.13 million23.61 millionN/AMIRA, ANEB, WHWK, and IFRX HeadlinesRecent News About These CompaniesWhitehawk Therapeutics (NASDAQ:WHWK) Raised to Hold at Zacks ResearchOctober 10, 2025 | marketbeat.comWhitehawk Therapeutics' (WHWK) Sell (E+) Rating Reaffirmed at Weiss RatingsOctober 8, 2025 | marketbeat.comWhitehawk Therapeutics to Participate in Upcoming Investor ConferencesSeptember 2, 2025 | prnewswire.comWhitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent HighlightsAugust 7, 2025 | prnewswire.comWhitehawk Therapeutics to Participate in the BTIG Virtual Biotechnology ConferenceJuly 22, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMIRA, ANEB, WHWK, and IFRX Company DescriptionsAnebulo Pharmaceuticals NASDAQ:ANEB$2.72 +0.26 (+10.57%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$2.70 -0.02 (-0.59%) As of 10/15/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.InflaRx NASDAQ:IFRX$1.25 -0.03 (-2.34%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$1.26 +0.01 (+0.80%) As of 10/15/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.MIRA Pharmaceuticals NASDAQ:MIRA$1.32 +0.01 (+0.76%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$2.24 +0.92 (+69.32%) As of 10/15/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.Whitehawk Therapeutics NASDAQ:WHWK$2.10 +0.13 (+6.60%) As of 10/15/2025 04:00 PM EasternAadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability 3 Healthcare Companies Insiders Are Buying Tempus AI Hits $100—Are Shares Due for a Pullback? Vertiv Stock Surges on Strategic CFO Hire and AI Momentum NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.